MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial

We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular lymphoma (FL) in the randomized GADOLIN trial (NCT01059630). Patients received obinutuzumab (G) plus bendamustine (Benda) induction followed by G maintenance, or Benda in...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Leukemia
Main Authors: Pott, Christiane, Sehn, Laurie H., Belada, David, Gribben, John, Hoster, Eva, Kahl, Brad, Kehden, Britta, Nicolas-Virelizier, Emmanuelle, Spielewoy, Nathalie, Fingerle-Rowson, Guenter, Harbron, Chris, Mundt, Kirsten, Wassner-Fritsch, Elisabeth, Cheson, Bruce D.
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group UK 2019
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7214251/
https://ncbi.nlm.nih.gov/pubmed/31462735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-019-0559-9
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker